2020 Prior Authorization Criteria

Total Page:16

File Type:pdf, Size:1020Kb

2020 Prior Authorization Criteria 2020 PRIOR AUTHORIZATION CRITERIA TABLE OF CONTENTS abiraterone tablet ...................................................................................................................... 217 ABRAXANE .............................................................................................................................. 131 ACTIMMUNE .............................................................................................................................. 14 ADASUVE ................................................................................................................................... 27 ADEMPAS ................................................................................................................................ 197 AFINITOR ................................................................................................................................. 217 AFINITOR DISPERZ ................................................................................................................. 217 AIMOVIG ..................................................................................................................................... 15 ALECENSA ............................................................................................................................... 217 ALIMTA ..................................................................................................................................... 131 ALIQOPA .................................................................................................................................. 131 alosetron tablet ........................................................................................................................... 17 ALUNBRIG ................................................................................................................................ 217 ambrisentan tablet .................................................................................................................... 199 AMITIZA ...................................................................................................................................... 19 ANADROL-50 ............................................................................................................................. 22 ANDRODERM ............................................................................................................................ 25 APOKYN ..................................................................................................................................... 29 ARCALYST ................................................................................................................................. 30 armodafinil tablet ......................................................................................................................... 31 ARRANON ................................................................................................................................ 131 ARZERRA ................................................................................................................................. 131 AUBAGIO .................................................................................................................................. 152 Updated 10/2019 VALUE PLUS 2020 1 AVASTIN ................................................................................................................................... 131 AVONEX ................................................................................................................................... 153 AVONEX PREFILLED KIT ........................................................................................................ 153 BALVERSA ............................................................................................................................... 217 BAVENCIO ............................................................................................................................... 172 BELEODAQ .............................................................................................................................. 131 BENLYSTA ................................................................................................................................. 34 benztropine tablet ..................................................................................................................... 122 BESPONSA .............................................................................................................................. 131 BETASERON ............................................................................................................................ 154 bexarotene capsule ................................................................................................................... 217 BLINCYTO ................................................................................................................................ 131 bosentan tablet ......................................................................................................................... 200 BOSULIF ................................................................................................................................... 217 BRAFTOVI 75 mg capsule ........................................................................................................ 217 CABOMETYX ........................................................................................................................... 217 CALQUENCE ............................................................................................................................ 217 CAPRELSA ............................................................................................................................... 217 CARBAGLU ................................................................................................................................ 75 CEREZYME .............................................................................................................................. 105 CHENODAL ................................................................................................................................ 76 CHLORPROMAZINE injection .................................................................................................... 27 chlorpromazine tablet .................................................................................................................. 27 CHORIONIC GONADOTROPIN ................................................................................................. 77 cinacalcet tablet .......................................................................................................................... 78 CINRYZE .................................................................................................................................. 114 Updated 10/2019 VALUE PLUS 2020 2 CLEMASTINE tablet ................................................................................................................. 122 clobazam suspension, tablet ....................................................................................................... 36 clorazepate tablet ........................................................................................................................ 39 COMETRIQ ............................................................................................................................... 217 COPAXONE .............................................................................................................................. 156 COPIKTRA ................................................................................................................................ 217 CORLANOR ................................................................................................................................ 81 COSENTYX ................................................................................................................................ 46 COTELLIC ................................................................................................................................ 217 CRESEMBA ................................................................................................................................ 82 CRYSVITA .................................................................................................................................. 83 cyclobenzaprine 5 mg, 10 mg tablet ......................................................................................... 123 CYRAMZA ................................................................................................................................ 131 CYSTAGON ................................................................................................................................ 86 CYSTARAN ................................................................................................................................ 85 DAKLINZA .................................................................................................................................. 87 dalfampridine ER tablet ............................................................................................................... 88 DALIRESP .................................................................................................................................. 89 danazol capsule .........................................................................................................................
Recommended publications
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • M2021: Pharmacogenetic Testing
    Pharmacogenetic Testing Policy Number: AHS – M2021 – Pharmacogenetic Prior Policy Name and Number, as applicable: Testing • M2021 – Cytochrome P450 Initial Presentation Date: 06/16/2021 Revision Date: N/A I. Policy Description Pharmacogenetics is defined as the study of variability in drug response due to heredity (Nebert, 1999). Cytochrome (CYP) P450 enzymes are a class of enzymes essential in the synthesis and breakdown metabolism of various molecules and chemicals. Found primarily in the liver, these enzymes are also essential for the metabolism of many medications. CYP P450 are essential to produce many biochemical building blocks, such as cholesterol, fatty acids, and bile acids. Additional cytochrome P450 are involved in the metabolism of drugs, carcinogens, and internal substances, such as toxins formed within cells. Mutations in CYP P450 genes can result in the inability to properly metabolize medications and other substances, leading to increased levels of toxic substances in the body. Approximately 58 CYP genes are in humans (Bains, 2013; Tantisira & Weiss, 2019). Thiopurine methyltransferase (TPMT) is an enzyme that methylates azathioprine, mercaptopurine and thioguanine into active thioguanine nucleotide metabolites. Azathioprine and mercaptopurine are used for treatment of nonmalignant immunologic disorders; mercaptopurine is used for treatment of lymphoid malignancies; and thioguanine is used for treatment of myeloid leukemias (Relling et al., 2011). Dihydropyrimidine dehydrogenase (DPD), encoded by the gene DPYD, is a rate-limiting enzyme responsible for fluoropyrimidine catabolism. The fluoropyrimidines (5-fluorouracil and capecitabine) are drugs used in the treatment of solid tumors, such as colorectal, breast, and aerodigestive tract tumors (Amstutz et al., 2018). A variety of cell surface proteins, such as antigen-presenting molecules and other proteins, are encoded by the human leukocyte antigen genes (HLAs).
    [Show full text]
  • Different Beta-Blocking Effects of Carvedilol and Bisoprolol in Humans
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 2001; 4 (1), 53-56 Different beta-blocking effects of carvedilol and bisoprolol in humans Koshucharova G, Klein W, Lercher P, Maier R, Stepan V Stoschitzky K, Zweiker R Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria ORIGINAL PAPERS, CLINICAL CARDIOLOGY Different Beta-Blocking Effects of Carvedilol and Bisoprolol J Clin Basic Cardiol 2001; 4: 53 Different Beta-Blocking Effects of Carvedilol and Bisoprolol in Humans G. Koshucharova, R. Zweiker, R. Maier, P. Lercher, V. Stepan, W. Klein, K. Stoschitzky Bisoprolol is a beta1-selective beta-adrenergic antagonist while carvedilol is a non-selective beta-blocker with additional blockade of alpha1-adrenoceptors. Administration of bisoprolol has been shown to cause up-regulation of β-adrenoceptor density and to decrease nocturnal melatonin release, whereas carvedilol lacks these typical effects of beta-blocking drugs. The objective of the present study was to investigate beta-blocking effects of bisoprolol and carvedilol in healthy subjects. We compared the effects of single oral doses of clinically recommended amounts of bisoprolol (2.5, 5 and 10 mg) and carvedilol (25, 50 and 100 mg) to those of placebo in a randomised, double-blind, cross-over study in 12 healthy male volun- teers. Three hours after oral administration of the drugs heart rate and blood pressure were measured at rest, after 10 min. of exercise, and after 15 min.
    [Show full text]
  • Tall Man Lettering List REPORT DECEMBER 2013 1
    Tall Man Lettering List REPORT DECEMBER 2013 1 TALL MAN LETTERING LIST REPORT WWW.HQSC.GOVT.NZ Published in December 2013 by the Health Quality & Safety Commission. This document is available on the Health Quality & Safety Commission website, www.hqsc.govt.nz ISBN: 978-0-478-38555-7 (online) Citation: Health Quality & Safety Commission. 2013. Tall Man Lettering List Report. Wellington: Health Quality & Safety Commission. Crown copyright ©. This copyright work is licensed under the Creative Commons Attribution-No Derivative Works 3.0 New Zealand licence. In essence, you are free to copy and distribute the work (including other media and formats), as long as you attribute the work to the Health Quality & Safety Commission. The work must not be adapted and other licence terms must be abided. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nd/3.0/nz/ Copyright enquiries If you are in doubt as to whether a proposed use is covered by this licence, please contact: National Medication Safety Programme Team Health Quality & Safety Commission PO Box 25496 Wellington 6146 ACKNOWLEDGEMENTS The Health Quality & Safety Commission acknowledges the following for their assistance in producing the New Zealand Tall Man lettering list: • The Australian Commission on Safety and Quality in Health Care for advice and support in allowing its original work to be either reproduced in whole or altered in part for New Zealand as per its copyright1 • The Medication Safety and Quality Program of Clinical Excellence Commission, New South
    [Show full text]
  • Bradykinin B2 Receptor Modulates Renal Prostaglandin E2 and Nitric Oxide
    (Hypertension. 1997;29:757-762.) © 1997 American Heart Association, Inc. Bradykinin B2 Receptor Modulates Renal Prostaglandin E2 and Nitric Oxide Helmy M. Siragy; Ayad A. Jaffa; Harry S. Margolius the Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville, and the Departments of Pharmacology and Medicine, Medical University of South Carolina and Ralph A. Johnson VA Medical Center, Charleston. Correspondence to Helmy M. Siragy, MD, Department of Medicine, Box 482, University of Virginia Health Sciences Center, Charlottesville, VA 22908. ABSTRACT Bradykinin and lys-bradykinin generated intrarenally appear to be important renal paracrine hormones. However, the renal effects of endogenously generated bradykinin are still not clearly defined. In this study, we measured acute changes in renal excretory and hemodynamic functions and renal cortical interstitial fluid levels of bradykinin, prostaglandin E2, and cGMP in response to an acute intrarenal arterial infusion of the bradykinin B2 receptor antagonist Hoe 140 (icatibant), cyclooxygenase inhibitor indomethacin, or nitric oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA) given individually or combined in uninephrectomized, conscious dogs (n=10) in low sodium balance. Icatibant caused a significant decrease in urine flow, urinary sodium excretion, and renal plasma flow rate (each P<.001). Glomerular filtration rate did not change during icatibant administration. Icatibant produced an unexpected large increase in renal interstitial fluid bradykinin (P<.0001) while decreasing renal interstitial fluid prostaglandin E2 and cGMP (each P<.001). Both indomethacin and L-NMMA when given individually caused significant antidiuresis and antinatriuresis and decreased renal blood flow (each P<.001). Glomerular filtration rate decreased during L-NMMA administration (P<.001) and did not change during indomethacin administration.
    [Show full text]
  • IHS National Pharmacy & Therapeutics Committee National
    IHS National Pharmacy & Therapeutics Committee National Core Formulary; Last Updated: 09/23/2021 **Note: Medications in GREY indicate removed items.** Generic Medication Name Pharmacological Category (up-to-date) Formulary Brief (if Notes / Similar NCF Active? available) Miscellaneous Medications Acetaminophen Analgesic, Miscellaneous Yes Albuterol nebulized solution Beta2 Agonist Yes Albuterol, metered dose inhaler Beta2 Agonist NPTC Meeting Update *Any product* Yes (MDI) (Nov 2017) Alendronate Bisphosphonate Derivative Osteoporosis (2016) Yes Allopurinol Antigout Agent; Xanthine Oxidase Inhibitor Gout (2016) Yes Alogliptin Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor DPP-IV Inhibitors (2019) Yes Anastrozole Antineoplastic Agent, Aromatase Inhibitor Yes Aspirin Antiplatelet Agent; Nonsteroidal Anti-Inflammatory Drug; Salicylate Yes Azithromycin Antibiotic, Macrolide STIs - PART 1 (2021) Yes Calcium Electrolyte supplement *Any formulation* Yes Carbidopa-Levodopa (immediate Anti-Parkinson Agent; Decarboxylase Inhibitor-Dopamine Precursor Parkinson's Disease Yes release) (2019) Clindamycin, topical ===REMOVED from NCF=== (See Benzoyl Peroxide AND Removed January No Clindamycin, topical combination) 2020 Corticosteroid, intranasal Intranasal Corticosteroid *Any product* Yes Cyanocobalamin (Vitamin B12), Vitamin, Water Soluble Hematologic Supplements Yes oral (2016) Printed on 09/25/2021 Page 1 of 18 National Core Formulary; Last Updated: 09/23/2021 Generic Medication Name Pharmacological Category (up-to-date) Formulary Brief
    [Show full text]
  • Carvedilol an 3.125, 6.25, 12.5 & 25 Mg Tablets
    Carvedilol AN 3.125, 6.25, 12.5 & 25 mg tablets Carvedilol AN Consumer Medicine Information What is in this leaflet Heart Failure: Carvedilol AN helps to lower your Heart failure occurs when the heart blood pressure. can no longer pump blood strongly This leaflet answers some of the Your doctor may have prescribed enough for the body's needs. Often common questions about Carvedilol Carvedilol AN for another reason. AN. It does not contain all the the heart grows in size to try to available information. It does not improve the blood flow but this can Ask your doctor if you have any take the place of talking to your make the heart failure worse. questions about why Carvedilol AN has been prescribed for you. doctor or pharmacist. Symptoms of heart failure include All medicines have risks and shortness of breath and swelling of benefits. Your doctor has weighed the feet or legs due to fluid build-up. the possible risks of Carvedilol AN Carvedilol AN reduces the pressure Before you take against the expected benefits. that the heart has to pump against as Carvedilol AN If you have any concerns about this well as controlling your heart rate. medicine talk to your doctor or Over 6 months or more this will pharmacist. reduce the size of an oversized heart When you must not take and increase its efficiency. Keep this leaflet until you have Cervedilol AN Carvedilol AN reduces the chances finished treatment with the You must not take Carvedilol AN medicine. of you being admitted to hospital if: You may need to read it again.
    [Show full text]
  • Role of the Intracellular Domains in the Regulation and the Signaling of the Human Bradykinin B2 Receptor
    Aus der Abteilung für Klinische Chemie und Klinische Biochemie in der Chirurgischen Klinik-Innenstadt der Ludwig-Maximilians-Universität München Leiterin der Abteilung: Prof. Dr. rer. nat. Dr. med. habil. Marianne Jochum Role of the intracellular domains in the regulation and the signaling of the human bradykinin B2 receptor Dissertation zum Erwerb des Doktorgrades der Humanbiologie an der Medizinischen Fakultät der Ludwig-Maximilians-Universität zu München Vorgelegt von Göran Wennerberg aus Stockholm 2010 Mit Genehmigung der Medizinischen Fakultät der Ludwig-Maximilians-Universität München Berichterstatter: PD Dr. rer. nat. Alexander Faussner Mitberichterstatter: Prof. Dr. Nikolaus Plesnila Prof. Dr. Franz-Xaver Beck Mitbetreuung durch den promovierten Mitarbeiter: Dekan: Prof. Dr. med. Dr. h.c. M. Reiser, FACR,FRCR Tag der mündlichen Prüfung: 27.01.2010 CONTENTS………………………………………………………………………………………I ABBREVIATIONS………………………………………………………………………………V A ZUSAMMENFASSUNG ............................................................................................ 1 B INTRODUCTION ....................................................................................................... 4 B.1 The kallikrein-kinin system (KKS) B.1.1 Historic background............................................................................................................................................4 B.1.2 Kinins...................................................................................................................................................................4
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Icatibant (Firazyr) Reference Number: CP.PHAR.178 Effective Date: 03/16 Coding Implications Last Review Date: 03/17 Revision Log
    Clinical Policy: Icatibant (Firazyr) Reference Number: CP.PHAR.178 Effective Date: 03/16 Coding Implications Last Review Date: 03/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description The intent of the criteria is to ensure that patients follow selection elements established by Centene® clinical policy for icatibant (Firazyr®). Policy/Criteria It is the policy of health plans affiliated with Centene Corporation® that Firazyr is medically necessary when one of the following criteria is met: I. Initial Approval Criteria A. Hereditary Angioedema (HAE) (must meet all): 1. Diagnosis of HAE confirmed by one of the following (a or b): a. Low C4 level and low C1-INH antigenic or functional level (see Appendix B); b. Normal C4 level and normal C1-INH levels, and all of the following (i - iii): i. History of recurrent angioedema; ii. Family history of angioedema; iii. Other types of angioedema have been ruled out (e.g., ACE-I/ARB-associated or other drug-induced angioedema, allergic angioedema, nonhistaminergic angioedema); 2. Prescribed for treatment of acute attacks; 3. Prescribed dose of Firazyr does not exceed 30 mg per dose (1 syringe per dose) with up to 3 doses administered in a 24 hour period. Approval duration: 12 months (no more than 6 doses per month) B. Other diagnoses/indications: Refer to CP.PHAR.57 - Global Biopharm Policy. II. Continued Approval A. Hereditary Angioedema (must meet all): 1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria; 2. Documentation of positive response to therapy; 3.
    [Show full text]
  • Ambetter 90-Day-Maintenance Drug List- 2020
    Ambetter 90-Day-Maintenance Drug List Guide to this list: What is Ambetter 90‐Day‐Maintenance Drug List? Ambetter 90‐Day‐Supply Maintenance Drug List is a list of maintenance medications that are available for 90 day supply through mail order or through our Extended Day Supply Network. How do I find a pharmacy that is participating in Extended Day Supply Network? To find a retail pharmacy that is participating in our Extended Day Supply Network please consult information available under Pharmacy Resources tab on our webpage. Alternatively, you can utilize our mail order pharmacy. Information on mail order pharmacy is available in Pharmacy Resources tab on our webpage. Are all formulary drugs covered for 90 day supply? No, certain specialty and non‐specialty drugs are excluded from 90 day supply. Please consult 90‐Day‐ Supply Maintenance Drug List for information if your drug is included. A Amitriptyline HCl Acamprosate Calcium Amlodipine Besylate Acarbose Amlodipine Besylate-Atorvastatin Calcium Acebutolol HCl Amlodipine Besylate-Benazepril HCl Acetazolamide Amlodipine Besylate-Olmesartan Medoxomil Albuterol Sulfate Amlodipine Besylate-Valsartan Alendronate Sodium Amlodipine-Valsartan-Hydrochlorothiazide Alendronate Sodium-Cholecalciferol Amoxapine Alfuzosin HCl Amphetamine-Dextroamphetamine Aliskiren Fumarate Anagrelide HCl Allopurinol Anastrozole Alogliptin Benzoate Apixaban Alosetron HCl Arformoterol Tartrate Amantadine HCl Aripiprazole Amiloride & Hydrochlorothiazide Armodafinil Amiloride HCl Asenapine Maleate Amiodarone HCl Aspirin-Dipyridamole
    [Show full text]